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Abstract
Background: There is a paucity of surrogate lung-specific biological markers that can be used to
track disease progression and predict clinical outcomes in chronic obstructive pulmonary disease
(COPD). The principal aim of this pilot study was to determine whether circulating surfactant
protein D (SPD) or Clara Cell protein-16 (CC16) levels are associated with lung function or health
status in patients with severe COPD.
Methods: We studied 23 patients with advanced COPD. Lung function measurements, Chronic
Respiratory Disease Questionnaire (CRQ) scores, and serum levels of SPD, CC16, and C-reactive
protein (CRP) were determined at baseline and at 3 months.
Results: At baseline, FEV1 was inversely associated with serum SPD levels (P = 0.045) but not with
CC16 (P = 0.675) or CRP levels (P = 0.549). Over a 3 month period, changes in SPD levels
correlated significantly with changes in CRQ scores (adjusted P = 0.008) such that patients who
had the largest declines in serum SPD levels experienced the largest gains in health status. The
association was particularly notable between circulating SPD level and the dyspnea domain of the
CRQ score (P = 0.018). Changes in CC16 or CRP levels did not correlate with changes in CRQ
scores.
Conclusion: Changes in serum SPD levels tracked well with changes in health status over a 3
month period in patients with severe COPD. These data suggest that circulating SPD levels may be
useful biomarkers to track health outcomes of COPD patients.
Background
Over 600 million people worldwide have chronic obstruc-
tive pulmonary disease (COPD) [1]. Dissimilar to most
other major causes of mortality in the world, COPD mor-
bidity and mortality continue to escalate at an alarming
rate [1]. The World Health Organization predicts by 2020,
COPD will to be the 3rd leading cause of mortality (cur-
rently 4th) and the 5th leading cause of morbidity (cur-
rently 12th) throughout the world [1]. Despite major
advances in the understanding of COPD pathophysiol-
ogy, there is a dearth of effective medications that can
modify its course [2]. One major limitation of drug devel-
opment has been the paucity of surrogate biological
markers that can be used to track disease progression (i.e.
progressive decline in lung function and increase in symp-
toms such as dyspnea) and predict clinical outcomes [3].
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COPD is a heterogeneous disorder with multiple different
(but related) phenotypes. The development of lung-based
biomarkers has been impeded by a variety of technical
and logistical factors including lack of standardization of
sample collection, invasiveness of the procedure and poor
patient tolerability [3]. Blood biomarkers are conceptu-
ally more appealing owing to the relative ease of procure-
ment and standardization of measurements.
Encouragingly, recent data suggest that certain inflamma-
tory biomarkers (e.g. C-reactive protein, CRP) correlate
with disease severity and with adverse health outcomes of
patients with mild to moderate disease [4]. However,
although CRP is a good predictor of cardiovascular events,
it is not a particularly good marker of respiratory health
outcomes or rate of decline in lung function [4]. This may
not be surprising given that the predominant source of cir-
culating CRP is the liver and not the lungs [5]. To capture
respiratory health events, lung-specific biomarkers are
desirable. Surfactant protein D (SPD) and Clara cell pro-
tein-16 (CC16) are two proteins that are produced pre-
dominantly in the lungs and as such may be useful in
tracking disease progression and health status of COPD
patients [6]. The principal aim of this pilot study was to
determine whether circulating SPD and CC16 are associ-
ated with lung function and health status of patients with
advanced COPD.
Methods
In this pilot study, we used serum samples obtained in a
recently completed trial of non-invasive mechanical ven-
tilation (NIMV) in advanced COPD patients. The details
of the trial are published elsewhere [7]. In brief, we
recruited study participants with a clinical diagnosis of
COPD and who were 40 years of age or older and had at
least a 10 pack-year history of cigarette smoking; forced
expiratory volume in one second (FEV1) to forced vital
capacity (FVC) ratio of less than 70% and a post-bron-
chodilator FEV1 that was less than 70% of predicted. At
each visit, patients performed spirometry using a rolling
seal spirometer and according to published American
Thoracic Society standards, as previously described [7]. At
these visits, the patients also completed the Chronic Res-
piratory Disease Questionnaire (CRQ) to assess their
health status. CRQ is an interviewer administered ques-
tionnaire, which asks patients to rate their health status in
four domains: dyspnea, fatigue, emotional function, and
mastery [8].
Venipuncture was also performed at each visit during day-
time. The samples were collected in plain tubes and were
allowed to clot for at least 30 minutes. They were then
centrifuged at 1500 × g for 15 minutes at room tempera-
ture, divided into aliquots using a sterile plastic transfer
pipette and frozen in -80°C conditions until use. The
samples were thawed once and SPD (Biovendor, Modrice,
Czech Republic), and CC16 levels (Biovendor, Modrice,
Czech Republic) were determined using commercially
available ELISA kits. They were measured in duplicate
with a coefficient of variation of 3.9% and 1.9%, respec-
tively. All samples from the same patient were included in
the same assay and were performed in duplicate with a
coefficient of variation of 3.9% and 1.9%, respectively.
The analytical limit of detection for SPD was 0.2 ng/mL,
with a sensitivity of 1.2 ng/mL and that for CC-16 was 20
pg/ml with an assay sensitivity of 500 pg/ml. Samples
were diluted 1:6 and all fell within the assay's detection
range. For benchmarking, in these samples, we also meas-
ured CRP levels using a highly sensitive commercially-
available solid-phase sandwich enzyme-linked immuno-
sorbent assay kits (Alpha Diagnostics, San Antonio, Tx).
Statistical analysis
There were 13 participants in NIMV group and 10 partici-
pants in control group. Two groups were similar in lung
function, SPD, CC16, and CRP levels at baseline and after
3 months of therapy [7]. Therefore, we combined the two
groups together for analytical purposes. As SPD, CC16,
and CRP were non-normally distributed, we log-trans-
formed these values to achieve normality. We then
employed linear regression techniques to determine
whether FEV1 or CRQ scores were associated with levels of
these biomarkers in the systemic circulation and whether
these biomarker levels were related to each other. We per-
formed these analyses for the cross-sectional data at base-
line as well as for the longitudinal data over 3 months of
follow-up. For the longitudinal component of the study,
we regressed the changes in the biomarker levels against
changes in FEV1 or CRQ scores. To control for potential
confounders, we conducted a stepwise regression analysis
in which covariates (age, sex, body mass index, PO2, PCO2
and FEV1) were added to the model one by one and
retained if the p-value was 0.15 or less in the multivariate
analysis. All tests were two-tailed in nature and were per-
formed using SAS software (version 9.1; SAS Institute;
Cary, NC). Continuous variables are expressed as mean ±
SD unless otherwise specified.
Results
There were 23 participants in the study: 11 men and 12
women. The average age was 65 years. All of the partici-
pants had advanced COPD with an average FEV1 of 31%
of predicted. At baseline, the median level of circulating
SPD, CC16, and CRP was 74.7 ng/mL, 4.6 µg/L, and 3.5
mg/L, respectively. The baseline demographic and clinical
characteristics are summarized in Table 1. The relation-
ship between SPD and these clinical characteristics at
baseline are summarized in Table 2.
At baseline, FEV1 was inversely associated with SPD levels
(P = 0.045) (Table 3, Figure 1) but not with CC16 (P =BMC Pulmonary Medicine 2007, 7:13 http://www.biomedcentral.com/1471-2466/7/13
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0.675) or CRP levels (P = 0.549) (Table 3). There was no
significant correlation between the three biomarkers at
baseline (Table 3). After 3 months of follow-up, the
changes in circulating SPD levels were significantly and
inversely associated with the changes in CRQ score (P =
0.010, adjusted P = 0.008) (Table 4). The association was
the strongest between circulating SPD levels and the dys-
pnea domain score of CRQ. As circulating SPD levels
increased, patients experienced increase in dyspnea (P =
0.018) and worse health status (Table 3, Figure 2). CRQ
scores were not associated with changes in CC16 or CRP
levels (Table 4). Moreover, there was no significant over-
lap in the changes of these biomarkers over time (Table
4). The results from the stepwise multivariate analysis
were similar to those obtained in the univariate analysis.
Discussion
COPD poses a major health burden worldwide, account-
ing for nearly 3 million deaths annually [1]. The develop-
ment of novel therapeutics for COPD has been impeded
by lack of good surrogate markers that can track disease
progression and predict clinical outcomes [3]. Biomarkers
derived from exhaled condensates, induced sputums and
bronchial fluids, while specific, have major shortcomings
including lack of standardization and difficulty in pro-
curement of samples that limit their application in large
clinical trials or studies. Blood biomarkers are more attrac-
tive because there are well established procedures for pro-
curement and processing of samples and standardization
of measurements. In COPD, the most widely studied
blood biomarker has been CRP. Although it performs well
in large cohorts, clinical application is limited owing to
the poor specificity of the measurement. Any inflamma-
tory or infectious insults whether or not they are linked
with COPD can modify CRP levels over time [9]. In the
present study, we evaluated two lung-specific blood
biomarkers as potential surrogates of health outcomes in
patients with severe COPD. We found that circulating
SPD was significantly associated with baseline lung func-
tion and changed with changing health status of COPD
patients over a 3 month period.
SPD is a large multimeric collagenous glycoprotein weigh-
ing ~43 kDa (half of the size of albumin) and is part of the
collectin family of proteins [10]. It is produced mainly by
type II pneumocytes in the lungs though other cells such
as pulmonary Clara cells, endothelial cells and glandular
cells in the gastrointestinal tract can produce small
amounts of SPD [11]. SPD plays an important role in
innate immunity and in host defense responses against
inhaled micro-organisms and allergens [11]. Addition-
ally, SPD has a major function in regulating surfactant
homeostasis in the lungs by modulating surfactant ultra-
structure and promoting reuptake of surfactant by type II
pneumocytes [12]. In general, under-expression of SPD in
the lung is associated with an increased risk of infections
[13], while local over-expression has been associated with
chronic inflammatory conditions such as asthma [14] and
interstitial pulmonary fibrosis [15]. The impact of circu-
lating SPD on lung function is not entirely clear. In the
present study, we found that at baseline FEV1  was
inversely correlated with log-SPD concentrations in the
serum such that the highest FEV1 values were observed in
patients with SPD levels less than 90 ng/ml. Similar find-
ings have been noted by Al-Salmi and colleagues [16] in a
group of pediatric patients with interstitial lung disease,
and by Krane and Griese [17] in a group of patients with
cystic fibrosis. Bronchial hyperresponsiveness may also
Table 2: The Relationship Between Circulating Surfactant 
Protein (SPD) Levelsand Clinical Characteristics
β-coefficient* R-value P value
Age (year) -0.014 ± 0.013 0.23 0.296
Male vs. female 0.138 ± 0.284 0.11 0.633
Body mass index (kg/m2) -0.005 ± 0.022 0.05 0.822
PaO2 (mmHg) -0.007 ± 0.015 0.11 0.629
PaCO2 (mmHg) 0.015 ± 0.0146 0.22 0.304
CRQ Score -0.089 ± 0.136 0.14 0.519
Dyspnea -0.225 ± 0.142 0.33 0.128
Fatigue -0.022 ± 0.109 0.04 0.844
Emotion 0.007 ± 0.114 0.01 0.950
Mastery -0.110 ± 0.101 0.23 0.288
Six-minute walk test (m) -0.001 ± 0.001 0.11 0.629
* Regression coefficient ± SE.
Abbreviations : CRQ – Chronic Respiratory Disease Questionnaire, 
SPD – surfactant protein D.
Table 1: Baseline characteristics of the study participants
Mean ± SD
Number 23
Age (year) 64.8 ± 10.6
Men (%) 11 (47.8%)
Body mass index (kg/m2) 27.7 ± 6.6
FEV1 (L) 0.84 ± 0.32
FEV1 (% predicted) 30.8 ± 14.8
PaO2 (mmHg) 58.6 ± 10.0
PaCO2 (mmHg) 44.5 ± 9.8
CRQ score 4.1 ± 1.1
Dyspnea 3.0 ± 1.0
Fatigue 3.5 ± 1.3
Emotion 4.9 ± 1.3
Mastery 4.5 ± 1.4
Six-minute walk test (m) 286.0 ± 123.6
SPD (ng/mL)* 74.7 (49.2–128.7)
CC16 (µg/L)* 4.6 (3.8–8.7)
CRP (mg/L)* 3.5 (1.1–9.8)
* Median and interquartile range.
Abbreviations: CC16 – Clara cell protein, CRP – C-reactive protein, 
SPD – Lung surfactant protein D, FEV1 – forced expiratory volume in 
one second.BMC Pulmonary Medicine 2007, 7:13 http://www.biomedcentral.com/1471-2466/7/13
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relate to increased SPD levels in serum or plasma. In a
group of asthmatics, Koopman and colleagues found that
serum SPD was associated with acute declines in FEV1 fol-
lowing allergen exposure [18]. Additionally, elevated cir-
culating SPD levels may predict poor clinical outcomes.
Among patients with acute respiratory distress syndrome
requiring mechanical ventilation, higher plasma SPD lev-
els are associated with a greater risk of multi-organ failure,
ventilator-dependence and mortality [19]. In the present
study, we found that increases in SPD were associated
with reduced health status and in particular with an
increase in dyspnea in patients with advanced COPD.
Collectively, these data suggest that elevated serum SPD is
a good marker of reduced lung function, worsening health
status (especially dyspnea) and other poor outcomes in
patients with lung disease. Thus, serum SPD is a promis-
ing biomarker for tracking disease progression and pre-
dicting clinical outcomes in COPD.
There were limitations to this study. Firstly, although the
study subjects were well characterized, the sample size was
small, increasing the risk for type I errors (i.e. false nega-
tive associations). Additionally, we performed multiple
statistical comparisons, which increased the probability
for type 2 errors (i.e. false positives). Larger studies will be
needed in the future to validate these initial findings. Sec-
ondly, nearly all of the patients in the study had severe or
very severe COPD. Thus, these data cannot be generalized
to patients with mild or moderate disease. Thirdly, we did
not measure biomarkers other than CRP, CC16 and SPD.
Thus, the use of other lung-specific molecules as potential
biomarkers in COPD is not certain. Fourthly, we did not
have any broncho-alveolar samples for measurement and
as such it is uncertain why FEV1 was inversely related to
The relationship between baseline serum Log-SPD levels and  baseline FEV1 Figure 1
The relationship between baseline serum Log-SPD 
levels and baseline FEV1. Black dot, NIMV group; White 
dot, Control group. Abbreviation: FEV1- forced expiratory 
volume in one second, SPD – surfactant protein D
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Table 3: The Relationship Between Lung function and Serum Protein Biomarkers at baseline
Baseline SPD* Baseline CC16* Baseline CRP*
β RP  v a l u e β RP  v a l u e β RP  v a l u e
Baseline FEV1 -0.204 0.42 0.045 -0.057 0.09 0.675 0.031 0.13 0.549
Baseline SPD* -- -- -0.293 0.23 0.295 0.080 0.17 0.446
Baseline CC16* -- -- -- -- -0.059 0.16 0.473
* Logarithmic scale.
A negative β-coefficient indicates an inverse relationship; whereas a positive β-coefficient indicates a positive linear relationship between the two 
variables.
Abbreviations : CC16 – Clara cell protein-16, CRP – C-reactive protein, FEV1 – forced expiratory volume in one second, SPD – surfactant protein 
D.
Relationship between the Changes in serum Log-SPD levels  and changes in the dyspnea Score over three months Figure 2
Relationship between the Changes in serum Log-
SPD levels and changes in the dyspnea Score over 
three months. Black dot, NIMV group; White dot, Control 
group. Abbreviation: SPD – surfactant protein D
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Table 4: Association between the changes in serum protein biomarkers, lung function, dyspnea score and total CRQ scores over 3 months
Change in SPD* Change in CC16* Change in CRP* Change in distance†
β RP β RP β RP β RP
Change in Dyspnea Score -1.95 (-1.95) 0.56 (0.56) 0.018 (0.018) -1.33 (-1.55) 0.24 (0.28) 0.359 (0.185) 0.42 (0.19) 0.23 (0.10) 0.367 (0.626) -14.63 (-16.91) 0.46 (0.52) 0.063 (0.032)
Change in CRQ Score -1.50 (-1.13) 0.61 (0.44) 0.010 (0.008) -1.52 (-2.01) 0.38 (0.49) 0.135 (0.011) -0.14 (-0.35) 0.10 (0.26) 0.688 (0.214) -15.67 (-15.67) 0.36 (0.36) 0.163 (0.163)
Change in SPD* -- -- 0.64 (0.64) 0.39 (0.39) 0.119 (0.119) 0.15 (0.15) 0.29 (0.08) 0.261 (0.261) 3.05 (3.05) 0.03 (0.03) 0.916 (0.916)
Change in CC16* -- -- -- -- 0.10 (0.10) 0.30 (0.30) 0.248 (0.182) 61.38 (88.51) 0.35 (0.46) 0.175 (0.611)
Change in CRP* -5.81 (-5.81) 0.10 (0.10) 0.698 (0.698)
* Logarithmic scale.
† Change in the distance of six-minute walk test (m).
Values in brackets were derived from a stepwise regression model in which age, sex, body mass index, PO2, PCO2 and FEV1 were included in the model.
Abbreviations: CC16 – Clara cell protein 16, CRP – C-reactive protein, CRQ – Chronic Respiratory Disease Questionnaire, SPD – surfactant protein D.BMC Pulmonary Medicine 2007, 7:13 http://www.biomedcentral.com/1471-2466/7/13
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serum SPD levels. Reduced lung expression of SPD is asso-
ciated with lung injury and poor lung function [20]. In
general, lung-based SPD measurements correlate posi-
tively with FEV1, while blood-based SPD measurements
correlate negatively with FEV1. Since lung is the major
source of SPD production, this observation suggests that
with lung injury, SPD and other similar proteins may leak
out from the lung compartments into the systemic circu-
lation [21], causing a paradoxical rise in serum SPD, even
in the presence of decreased lung production, a notion
that is supported by animal experiments [22]. There were
several other notable observations in our study. Firstly,
although the baseline FEV1 correlated with SPD, FEV1
failed to change as a function of SPD over 3 months. One
possibility is that these two variables may not be causally
related. Alternatively and more likely is that the 3 month
follow-up may have been too short to observe any signif-
icant changes in FEV1. A larger and longer duration study
is needed to confirm these preliminary observations. Sec-
ondly, although the changes in SPD related to changes in
the CRQ scores, especially with the dyspnea scores over 3
months, the baseline CRQ scores were not significantly
associated with baseline SPD scores. One potential expla-
nation for this apparent paradox was the relative small
spread of CRQ scores of study participants at baseline. Vir-
tually all patients complained of poor health status (mean
CRQ score of 4.1 with a SD of 1.1), which made it statis-
tically difficult to detect any significant relationships with
CRQ. A larger study with a wider variation of CRQ scores
among study participants is needed to confirm these rela-
tionships.
Conclusion
In summary, the present study suggests that in advanced
COPD, serum SPD level is negatively associated with
FEV1, and its increase over a 3-month period is associated
with worsening of health status of patients. Serum SPD is
a promising lung-specific biomarker to track clinical
health outcomes of patients with COPD, pending valida-
tion of these early findings with larger clinical studies.
CC16: Clara Cell protein-16
COPD: Chronic Obstructive Pulmonary Disease
CRP: C-reactive protein
FEV1: forced expiratory volume in one second
FVC: forced vital capacity
NIMV: non-invasive mechanical ventilation
SPD: surfactant protein D
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